Company Description
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of solid and liquid tumors.
Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM and other cancers; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation.
The company develops INB-300 and INB-500 that are in preclinical phase for treatment of acute myeloid leukemia, and other solid and hematological tumor types.
The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020.
IN8bio, Inc. was incorporated in 2016 and is based in New York, New York.
| Country | United States |
| Founded | 2016 |
| IPO Date | Jul 30, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 31 |
| CEO | Tai-Wei Ho |
Contact Details
Address: 350 5th Avenue, Suite 5330 New York, New York 10118 United States | |
| Phone | 646 600 6438 |
| Website | in8bio.com |
Stock Details
| Ticker Symbol | INAB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 0001740279 |
| CUSIP Number | 45674E109 |
| ISIN Number | US45674E1091 |
| Employer ID | 82-5462585 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Tai-Wei Ho | Co-Founder, President, Chief Executive Officer and Director |
| Patrick McCall CPA | Chief Financial Officer and Secretary |
| Dr. Lawrence S. Lamb Ph.D. | Executive Vice President, Co-Founder and Chief Scientific Officer |
| Dr. Kate Rochlin Ph.D. | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 12, 2024 | EFFECT | Notice of Effectiveness |
| Nov 12, 2024 | 424B3 | Prospectus |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 4, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Oct 15, 2024 | D | Notice of Exempt Offering of Securities |
| Oct 11, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Oct 9, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 1, 2024 | 8-K | Current Report |
| Sep 17, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |